Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

3.250 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
From FN Media Group LLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Recap: Lantern Pharma Q4 Earnings ↗
 
Via Benzinga
News headline image
Lantern Pharma Earnings Preview ↗
 
Via Benzinga
News headline image
Lantern Pharma: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
A Preview Of Lantern Pharma's Earnings ↗
 
Via Benzinga
News headline image
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 ↗
LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
From Lantern Pharma Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 18, 2024 ↗
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
From Lantern Pharma Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. 
Via Benzinga
News headline image
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
From Lantern Pharma Inc.
Via Business Wire
News headline image
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD ↗
Grand View Research says the global 
Via Talk Markets
News headline image
3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom ↗
Discover how these AI powerhouses are leveraging AI in the IT consulting, application software, and biotech industries. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics ↗
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
From Lantern Pharma Inc.
Via Business Wire
News headline image
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
From Lantern Pharma
Via Business Wire
News headline image
AI-Focused Drug Discovery Stocks Index Up 26% In December ↗
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week ↗
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
The 3 Most Undervalued AI Penny Stocks to Buy in December ↗
These AI penny stocks offer substantial returns to investors as the market continues to grow at a rapid pace. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
From Lantern Pharma Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.